These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [A hematocrit greater than 36 lessens mortality and hospitalization in hemodialysis]. Fernández-Gallego J; Gutiérrez C Nefrologia; 2003; 23(2):177-8. PubMed ID: 12778885 [No Abstract] [Full Text] [Related]
3. Recombinant human erythropoietin in patients with anemia due to end-stage renal disease. US multicenter trials. Sobota JT Contrib Nephrol; 1989; 76():166-78; discussion 212-8. PubMed ID: 2684519 [No Abstract] [Full Text] [Related]
7. [Therapy of renal anemia with recombinant human erythropoietin]. Schaefer RM; Kürner B; Zech M; Krahn R; Heidland A Dtsch Med Wochenschr; 1988 Jan; 113(4):125-9. PubMed ID: 3276487 [TBL] [Abstract][Full Text] [Related]
8. Subcutaneous recombinant erythropoietin in the treatment of renal anaemia in CAPD patients. Macdougall IC; Cavill I; Davies ME; Hutton RD; Coles GA; Williams JD Contrib Nephrol; 1989; 76():219-26. PubMed ID: 2582780 [No Abstract] [Full Text] [Related]
9. The MAXIMA trial. Nonoguchi H; Izumi Y; Nakayama Y; Kohda Y; Tomita K Lancet; 2008 Jan; 371(9609):299-300; author reply 300. PubMed ID: 18294989 [No Abstract] [Full Text] [Related]
10. Hemoglobin variability in dialysis patients. Brimble KS; Clase CM J Am Soc Nephrol; 2007 Aug; 18(8):2218-20. PubMed ID: 17627931 [No Abstract] [Full Text] [Related]
11. Effect on hemoglobin F synthesis by erythropoietin in patients with anemia of end-stage renal disease maintained by chronic hemodialysis. Salvati F; Strippoli P; Barchetti M; Scatizzi A Nephron; 1992; 60(3):371. PubMed ID: 1373475 [No Abstract] [Full Text] [Related]
12. Once-weekly epoetin-beta in renal anemia: the clinical evidence. Albertazzi A Contrib Nephrol; 2002; (137):408-11. PubMed ID: 12101986 [No Abstract] [Full Text] [Related]
13. Subcutaneous erythropoietin in the treatment of renal anaemia. Drinovec J; Varl J Przegl Lek; 1992; 49(1-2):38-40. PubMed ID: 1455004 [TBL] [Abstract][Full Text] [Related]
14. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis]. Martínez Castelao A; Reyes A; Valdés F; Otero A; López de Novales E; Pallardó L; Tabernero JM; Hernández Jaras J; Lladós F Nefrologia; 2003; 23(2):114-24. PubMed ID: 12778875 [TBL] [Abstract][Full Text] [Related]
15. Target hemoglobin level for EPO therapy in CKD. Parfrey PS Am J Kidney Dis; 2006 Jan; 47(1):171-3. PubMed ID: 16377399 [No Abstract] [Full Text] [Related]
16. Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: a parallel, randomized, double blind study. Pérez-Oliva JF; Casanova-González M; García-García I; Porrero-Martín PJ; Valenzuela-Silva CM; Hernández-Montero T; Lagarde-Ampudia M; Casanova-Kutsareva Y; Avila-Albuerne Y; Vargas-Batista A; Bobillo-López H; Herrera-Valdés R; López-Saura PA; BMC Nephrol; 2005 May; 6():5. PubMed ID: 15910687 [TBL] [Abstract][Full Text] [Related]
17. Erythropoietin treatment for anemia in end-stage renal disease with diabetes mellitus. Nakatsuka K; Hino M; Miki T; Nishizawa Y; Tabata T; Inoue T; Morii H Diabetes Care; 1990 Nov; 13(11):1130-1. PubMed ID: 2261828 [No Abstract] [Full Text] [Related]
18. Erythropoietin. Haberl M Aust Nurses J; 1990 Sep; 20(2):29. PubMed ID: 2268202 [No Abstract] [Full Text] [Related]
19. Changes in anemia management and hemoglobin levels following revision of a bundling policy to incorporate recombinant human erythropoietin. Hasegawa T; Bragg-Gresham JL; Pisoni RL; Robinson BM; Fukuhara S; Akiba T; Saito A; Kurokawa K; Akizawa T Kidney Int; 2011 Feb; 79(3):340-6. PubMed ID: 20962740 [TBL] [Abstract][Full Text] [Related]